A Study to Test Different Doses of BI 456906 in Patients With Obesity

Sponsor
Boehringer Ingelheim
Study ID
NCT03591718
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • BI 456906 — DRUG
    Solution for injection
  • Placebo — DRUG
    solution for injection

Study Details

Main objective is to investigate the tolerability of different titration schemes of BI 456906 in otherwise healthy patients with obesity/overweight, and to determine a titration scheme for future studies.

Key Dates

Start date
Jul 26, 2018
Status verified
Mar 2021
Primary completion
Apr 20, 2020
Completion
Apr 30, 2020

Study Design

Enrollment
131 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: BI 456906
  • Experimental: Placebo

Primary Outcome Measure

Cumulative number [N (%)] of patients withdrawn from up-titration by up-titration scheme [ Time Frame: Up to 132 days ]

Related Studies